CD274 and neoplasm: Given the inherent tumor heterogeneity, the creation of a comprehensive framework that amalgamates PD-L1 expression status, tumor mutational burden (TMB), personalized immune profiling, genomic, transcriptomic, and microbiome data could substantially enhance predictive accuracy and facilitate future interventions [4, 10].